Residual microvascular risk in diabetes: unmet needs and future directions (Q37622065)

21 August 2017

1 reference

title

Residual microvascular risk in diabetes: unmet needs and future directions (English)

1 reference

21 August 2017

0 references

Paola Fioretto

1

1 reference

21 August 2017

Paul M Dodson

series ordinal

2

1 reference

21 August 2017

Dan Ziegler

series ordinal

3

1 reference

21 August 2017

Robert S Rosenson

series ordinal

4

1 reference

21 August 2017

1 January 2010

1 reference

Nature Reviews Endocrinology

21 August 2017

1 reference

21 August 2017

6

1 reference

21 August 2017

19-25

1 reference

21 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2009.213

21 August 2017

0 references

cites work

Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Meta-analysis: the effect of statins on albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Microcirculatory dysfunction in cardiac syndrome X: role of abnormal blood rheology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Early microvascular dysfunction in healthy normal-weight males with heredity for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Effects of intensive glucose lowering in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Effect of a multifactorial intervention on mortality in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Evidence for the involvement of miRNA in redox regulated angiogenic response of human microvascular endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Factors associated with avoidance of severe complications after 25 yr of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

PPAR activators inhibit endothelial cell migration by targeting Akt.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Pleiotropic effects of fenofibrate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Fibrates and microvascular complications in diabetes--insight from the FIELD study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Statins for improving renal outcomes: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

31 March 2020

Statins and proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Statin safety: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

The dyslipidemia of chronic renal disease: effects of statin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Fenofibrate increases creatininemia by increasing metabolic production of creatinine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Fish Oil in Diabetic Nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Vascular risk factors and diabetic neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Benefits of statin treatment in cardiac syndrome-X

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Decrease in coronary blood flow reserve during hyperlipidemia is secondary to an increase in blood viscosity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Glitazone use associated with diabetic macular edema

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.213

Higher levels of HDL cholesterol are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes

31 March 2020

1 reference

12 December 2020

[Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent]

1 reference

12 December 2020

Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18.

1 reference

12 December 2020

Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium.

1 reference

12 December 2020

Effect of a modified fibrate (Biniwas Retard) on hemorheological alterations in hyperlipemic patients.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2009.213

1 reference

Dimensions Publication ID

21 August 2017

0 references

1 reference